Provided By GlobeNewswire
Last update: Sep 25, 2025
BROOMFIELD, Colo., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that the UHealth – University of Miami Health System and the Miller School of Medicine enrolled its first two patients in the CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial. The pivotal CLARITY study is designed to demonstrate Nociscan’s clinical and economic value in spine surgery.
Read more at globenewswire.com0.0571
-0.05 (-44.62%)
8.95
-0.74 (-7.64%)
Find more stocks in the Stock Screener